CTLT Stock Cash Flow Statements

Catalent Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Catalent Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2020-12-31	2020-09-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30

cash flows from operating activities:
net income	-129,000,000	23,000,000	-101,000,000	-206,000,000	-759,000,000	-110,000,000	-227,000,000			188,000,000	141,000,000	97,000,000	93,000,000	182,400,000	170,800,000	82,400,000	66,500,000	45,600,000		71,100,000				82,700,000			3,800,000		26,000,000	17,400,000	4,600,000		9,800,000
adjustments to reconcile net income to net cash from operations:
depreciation and amortization	113,000,000	130,000,000	126,000,000	121,000,000	112,000,000	114,000,000	106,000,000	103,000,000	99,000,000	100,000,000	99,000,000	98,000,000	81,000,000	73,000,000	140,100,000	69,100,000	187,300,000	122,500,000	60,600,000	54,700,000	66,400,000	54,600,000	52,900,000	52,600,000	51,700,000	46,800,000	39,000,000	38,700,000	36,500,000	35,500,000	35,800,000	35,100,000	34,800,000	35,200,000	35,500,000	36,200,000	34,400,000	35,200,000	35,000,000
goodwill impairment charges		0	0	-2,000,000	689,000,000	0
non-cash foreign currency transaction (gain) loss	-10,000,000					-3,000,000							9,000,000		-12,000,000
amortization of debt issuance costs	3,000,000		4,000,000	4,000,000	2,000,000		2,000,000	2,000,000	2,000,000		1,000,000	2,000,000	2,000,000
impairments charges and loss/gain on sale of assets	4,000,000			15,000,000	-1,000,000		5,000,000	1,000,000	-2,000,000
gain on sale of subsidiary	-17,000,000										0	0	-1,000,000
stock-based compensation	17,000,000	16,000,000	17,000,000	16,000,000	19,000,000	0	6,000,000	10,000,000	19,000,000	12,000,000	10,000,000	11,000,000	21,000,000	12,500,000	30,100,000						6,600,000	7,500,000	10,000,000
benefit from deferred income taxes	-5,000,000		3,000,000	17,000,000	-44,000,000			17,000,000	-4,000,000	1,000,000	12,000,000
benefit from bad debts and inventory	39,000,000	-5,000,000	43,000,000	34,000,000	10,000,000	44,000,000	32,000,000	39,000,000	28,000,000	3,000,000	5,000,000	-1,000,000	10,000,000	1,000,000	18,400,000	7,900,000	11,400,000	9,400,000	4,100,000	1,900,000	5,500,000	2,300,000	2,800,000	2,000,000	1,400,000	-1,400,000	4,900,000	5,400,000	2,300,000	1,300,000	2,000,000	5,000,000	1,100,000	6,200,000	900,000	3,200,000	2,300,000	5,500,000	1,700,000
change in operating assets and liabilities:
decrease in trade receivables	173,000,000		-35,000,000	5,000,000	160,000,000		-130,000,000	117,000,000	31,000,000			-54,000,000	185,000,000		87,600,000	143,700,000		4,300,000
increase in inventories	-10,000,000		-15,000,000	-15,000,000	-31,000,000	-57,000,000	45,000,000	-95,000,000	-85,000,000	-35,000,000	55,000,000	-85,000,000	-63,000,000	-20,000,000	-140,300,000
decrease in accounts payable	-10,000,000		-18,000,000	33,000,000	-73,000,000				-52,000,000									-13,300,000
other assets/accrued liabilities, net—current and non-current	-107,000,000		-33,000,000	78,000,000	-163,000,000		-64,000,000	-26,000,000	-155,000,000		-79,000,000	-49,000,000	-165,000,000		-68,800,000	-93,400,000	-48,400,000	-49,300,000	-52,700,000
net cash from operating activities	61,000,000	214,000,000	12,000,000	112,000,000	-70,000,000	196,000,000	-64,000,000	214,000,000	-92,000,000	69,000,000	138,000,000	69,000,000	163,000,000	134,300,000	223,700,000	149,700,000	267,600,000	145,900,000	25,200,000	87,900,000	75,300,000	43,300,000	41,200,000	103,300,000	95,200,000	92,300,000	83,700,000
capex	18,000,000	0	-8,000,000	0	21,000,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-88,800,000	-48,000,000	-43,000,000	-38,300,000	-58,800,000	-34,800,000	-40,200,000	-42,700,000
free cash flows	79,000,000	214,000,000	4,000,000	112,000,000	-49,000,000	196,000,000	-64,000,000	214,000,000	-92,000,000	69,000,000	138,000,000	69,000,000	163,000,000	134,300,000	223,700,000	149,700,000	267,600,000	145,900,000	25,200,000	-900,000	27,300,000	300,000	2,900,000	44,500,000	60,400,000	52,100,000	41,000,000
cash flows used in investing activities:
acquisition of property, equipment, and other productive assets	-57,000,000		-74,000,000	-94,000,000	-84,000,000		-138,000,000	-168,000,000	-149,000,000		-148,000,000	-123,000,000	-154,000,000		-338,900,000	-149,600,000	-303,500,000	-152,200,000	-73,500,000
proceeds from sale of property and equipment		0	0	0	1,000,000	0	1,000,000	1,000,000	6,000,000						300,000					100,000				0	0			0	-600,000
proceeds from sale of subsidiary	23,000,000
payment for investments		1,000,000	0				-1,000,000
net cash from investing activities	-34,000,000	-74,000,000	-74,000,000	-95,000,000	-84,000,000	-121,000,000	-110,000,000	-608,000,000	-116,000,000	-394,000,000	-191,000,000	-1,132,000,000	-167,000,000	-213,100,000	-354,400,000	-151,200,000
cash flows from financing activities:
proceeds from borrowing					115,000,000		90,000,000	550,000,000	75,000,000				1,096,000,000	-2,600,000			1,109,100,000							0	0			0	0	322,400,000	75,000,000					0	0
payments related to long-term obligations	-5,000,000		-249,000,000	-687,000,000	-35,000,000		-144,000,000	-25,000,000	-7,000,000	-6,000,000	-8,000,000	-61,000,000	-3,000,000	-12,200,000	-54,800,000	-2,400,000	-808,900,000	-51,500,000	-3,300,000	-782,300,000	-4,600,000	-48,700,000	-454,700,000	-4,700,000	-4,800,000	-4,700,000	-4,700,000	-4,600,000	-4,700,000	-204,500,000	-4,700,000	-4,700,000	-4,600,000	-4,600,000	-4,700,000	-5,000,000	-5,500,000	-5,500,000	-863,800,000
financing fees paid		0	0	-15,000,000	-1,000,000	0	0			0	0	0	-15,000,000	-300,000			-25,100,000							0	0				0
cash received, in lieu of equity, for tax-withholding obligations	1,000,000
exercise of stock options	1,000,000	0	8,000,000	0	1,000,000	0	3,000,000	0	1,000,000	5,000,000	2,000,000	11,000,000	8,000,000	15,900,000
other financing activities	-7,000,000	-5,000,000	-4,000,000	-12,000,000	18,000,000	3,000,000	26,000,000	4,000,000	3,000,000	3,000,000	3,000,000	2,000,000	4,000,000	3,800,000	3,700,000
net cash from financing activities	-10,000,000	-10,000,000	0	-14,000,000	98,000,000	-51,000,000	-25,000,000	523,000,000	74,000,000	1,000,000	-3,000,000	-49,000,000	1,082,000,000	-17,300,000	-7,200,000										-7,800,000	419,400,000	263,000,000
effect of foreign currency exchange on cash and cash equivalents	29,000,000		-5,000,000	17,000,000	-15,000,000		9,000,000	32,000,000	-34,000,000		-7,000,000	-8,000,000	-5,000,000
net increase in cash and cash equivalents	46,000,000								-168,000,000				1,073,000,000
cash and cash equivalents at beginning of period	289,000,000		0	0	280,000,000		0	0	449,000,000		0	0	896,000,000
cash and cash equivalents at end of period	335,000,000		-67,000,000	20,000,000	209,000,000		-190,000,000	161,000,000	281,000,000		-63,000,000	-1,120,000,000	1,969,000,000
supplementary cash flow information:
interest paid	68,000,000	44,000,000	70,000,000	47,000,000	65,000,000	43,000,000	62,000,000	37,000,000	46,000,000	23,000,000	43,000,000	10,000,000	40,000,000	8,000,000	52,000,000	43,400,000	88,700,000	47,700,000	24,800,000	27,900,000	22,400,000	22,700,000	29,500,000	26,000,000	15,700,000	24,800,000	16,700,000	26,000,000	15,400,000	19,200,000	20,200,000	19,800,000	21,600,000	20,200,000	20,800,000	20,600,000	19,500,000	22,700,000	44,300,000
income taxes paid	9,000,000	-21,000,000	33,000,000	12,000,000	19,000,000	16,000,000	45,000,000	27,000,000	11,000,000	13,000,000	13,000,000	12,000,000	15,000,000	22,200,000	18,900,000	8,800,000	38,900,000	19,600,000	12,700,000	6,800,000	11,000,000	9,600,000	14,800,000	15,600,000	300,000	100,000	7,900,000	14,000,000	6,100,000	8,800,000	10,900,000	10,400,000	10,200,000	10,000,000	10,000,000	10,300,000	5,600,000	8,200,000	9,900,000
non-cash purchase of property, equipment, and other productive assets	18,000,000		-8,000,000	0	21,000,000
adjustments to reconcile net earnings to net cash from operations:
amortization of debt financing costs
non-cash restructuring charges		0	0			0	11,000,000
impairment charges and loss/gain on sale of assets		2,000,000
benefit for deferred income taxes													-8,000,000			-10,600,000	5,400,000	2,700,000
pension settlement charges		0	9,000,000
other operating activities
decrease (increase) in trade receivables
decrease (increase) in inventories
increase in accounts payable										71,000,000	-37,000,000	9,000,000	-6,000,000	13,400,000	13,400,000		29,900,000
other assets/accrued liabilities, net - current and non-current																										-15,600,000	-60,500,000	33,300,000	37,000,000	0	-23,600,000
acquisition of property and equipment
proceeds from maturity (purchases) of marketable securities
settlement on sale of subsidiaries												0	-3,000,000
payment for acquisitions, net of cash acquired						0	0			-166,000,000	-13,000,000	-994,000,000	-26,000,000	100,000	-14,800,000		-379,700,000	-10,700,000	-10,700,000	-1,163,500,000	0	0	-127,500,000	0	0				-84,200,000	1,200,000	-86,900,000
proceeds from borrowings		140,000,000	245,000,000							0	0
payments related to financing obligations
dividends paid										0	0	0	-4,000,000	-4,300,000	-13,000,000	-8,100,000	-28,100,000	-20,000,000	-11,900,000
cash paid, in lieu of equity, for tax withholding obligation
effect of foreign currency on cash																								-20,300,000	9,400,000	-600,000	9,100,000	6,000,000	7,900,000	-9,900,000	900,000	-2,600,000	0	-2,600,000	-1,300,000	2,100,000	-4,800,000	-3,300,000	-13,600,000
net increase in cash and equivalents
cash and equivalents at beginning of period															953,200,000	953,200,000	345,400,000	345,400,000	345,400,000	0	0	0	410,200,000	0	0	0	288,300,000	0	0	0	131,600,000	0	0	0	151,300,000	0	0	0	74,400,000
cash and equivalents at end of period															833,100,000	1,007,000,000	608,400,000	188,900,000	243,400,000	117,500,000	20,000,000	-58,200,000	266,100,000	18,700,000	62,000,000	-271,900,000	601,400,000	47,100,000	-14,600,000	123,700,000	132,100,000	-2,300,000	18,400,000	-35,900,000	151,400,000	35,200,000	32,000,000	20,900,000	63,200,000
supplementary disclosure of non-cash investing and financing activity:
issuance of common stock from partial conversion of redeemable preferred stock
non-cash purchase of property, equipment
fiscal year ended june 30, 2024
manufacturing & commercial product supply															124,400,000	89,900,000	217,600,000	245,000,000	242,000,000
development services & clinical supply
total															403,900,000	377,100,000	242,300,000	267,900,000	263,700,000
inter-segment revenue elimination
combined net revenue
adjustments to reconcile net income to net cash from operating activities:
non-cash foreign currency transaction gain											0					-3,800,000
proceeds from maturity of marketable securities												-16,000,000	20,000,000
net decrease in cash and cash equivalents			-67,000,000	20,000,000	-71,000,000		-190,000,000
non-cash foreign currency transaction loss				2,000,000	9,000,000			-26,000,000	27,000,000								2,500,000	5,500,000
(payment) proceeds for investments					-1,000,000
financing-related charges											0	0	4,000,000
gain on derivative instrument										0	0	0	-2,000,000		-16,000,000			-1,400,000
(settlement on) proceeds from sale of subsidiaries										0
payment made for investments										2,000,000	-1,000,000	1,000,000	-4,000,000	-26,900,000	-1,000,000	-1,600,000	-2,400,000	-2,000,000	-700,000	-500,000
proceeds from sale of common stock														200,000	81,800,000	83,600,000	494,200,000			200,000	-200,000	0	445,500,000	0	0
net decrease in cash and equivalents															-120,100,000
note receivable from sale of blow-fill-seal business
fiscal year ended june 30, 2023
(benefit from) benefit from deferred income taxes															-5,300,000
proceeds from maturity of (purchase of) marketable securities
cash paid, in lieu of equity, for tax-withholding obligations											0	-5,000,000	-4,000,000		-26,400,000	-19,600,000	-25,300,000	-24,400,000	-18,100,000		-2,300,000	-5,900,000	-5,100,000
proceeds from sale of marketable securities								37,000,000	24,000,000
proceeds from (payment for) investments									3,000,000
cash received (paid), in lieu of equity, for tax-withholding obligations									2,000,000
non-cash foreign currency transaction losses (gains)
amortization and write-off of debt financing costs															3,300,000	1,700,000	10,700,000	3,100,000	1,500,000	7,100,000	1,000,000	900,000	5,200,000	1,100,000
asset impairments charges and gain/loss on sale of assets
(gain) loss on sale of subsidiary														2,000,000
financing related charges
increase in trade receivables														-184,800,000
cash flows from investing activities:
acquisition of property and equipment and other productive assets																				-88,800,000	-48,000,000	-43,000,000	-38,300,000	-58,800,000	-34,800,000	-40,200,000	-42,700,000	-52,000,000	-33,700,000	-26,400,000	-27,700,000	-31,800,000	-25,300,000	-49,300,000	-33,200,000	-32,300,000	-37,400,000	-40,100,000	-31,200,000
purchases of marketable securities										5,000,000				2,900,000
fiscal year ended june 30, 2022
development services															279,500,000	287,200,000	24,700,000	22,900,000	21,700,000
clinical supply services
impairments charges and gain on sale of assets											2,000,000
impairments charges and (gain) loss on sale of assets													3,000,000
net change in other borrowings														400,000	1,500,000	-3,900,000	-45,200,000	-5,900,000	-2,500,000	-1,900,000	-1,600,000	-400,000	-4,500,000	-500,000	-2,000,000	1,100,000	-1,700,000	100,000	-300,000	-1,300,000	-4,300,000
non-cash foreign currency transaction (gains) losses
asset impairments charges and (gain) loss on sale of assets															2,400,000
proceeds from sale of subsidiaries														200,000			20,800,000	20,800,000						0	0
proceeds from sale of preferred stock
fiscal year ended june 30, 2021
(gain) loss on derivative instrument
prepayment for pending business acquisition																		-55,100,000
effect of foreign currency exchange on cash															17,800,000	5,700,000	-10,500,000	-1,400,000	-6,500,000		2,300,000	-3,500,000	-700,000
three months ended december 31, 2020
adjustments to reconcile earnings from operations to net cash from operations:
asset impairments charges and /loss on sale of assets																1,800,000	2,100,000	1,500,000
(gain) / loss on derivative instrument																-9,000,000
equity compensation																18,700,000	35,500,000	26,900,000	16,600,000					6,100,000	5,600,000	8,500,000	7,000,000	4,500,000	4,600,000	4,900,000	6,900,000	2,300,000	3,400,000	2,600,000	2,500,000	2,600,000	2,100,000	2,800,000	1,500,000
(increase)/decrease in inventories																-65,400,000
increase/(decrease) in accounts payable																6,600,000			-47,300,000		17,200,000	7,000,000	-18,300,000	17,000,000	15,700,000	-2,400,000	2,000,000	22,300,000	2,200,000	-13,400,000	-1,200,000	14,800,000	1,200,000	3,800,000	1,600,000	2,300,000	7,500,000	4,800,000	-26,300,000
net cash provided by/(used in) financing activities																49,600,000													-7,300,000	109,800,000	65,900,000
net increase/(decrease) in cash and equivalents																53,800,000	263,000,000	-156,500,000	-102,000,000	117,500,000	20,000,000	-58,200,000	-144,100,000	18,700,000	62,000,000	-271,900,000	313,100,000	47,100,000	-14,600,000	123,700,000	500,000	-2,300,000	18,400,000	-35,900,000	100,000	35,200,000	32,000,000	20,900,000	-11,200,000
three months ended september 30, 2020
non-cash foreign currency transaction (gains)/losses
asset impairments charges and (gain)/loss on sale of assets																			-200,000	2,400,000	-100,000	-100,000	2,900,000
reclassification of financing fees paid																								0	0
(gain)/loss on derivative instrument																			8,900,000
provision/(benefit) for deferred income taxes																			-600,000	-14,400,000	-600,000	-1,300,000	1,200,000	-4,900,000	4,700,000	37,400,000	-1,800,000	-2,100,000	-100,000	5,000,000	-4,100,000	-18,700,000	2,900,000	1,700,000	-1,200,000	-93,700,000	-1,300,000	-18,000,000	-7,700,000
(increase) in trade receivables
(increase) in inventories
net cash (used in) investing activities																	-664,800,000	-199,200,000	-84,900,000	-1,252,700,000	-48,900,000	-43,000,000	-165,800,000	-58,800,000	-34,800,000	-783,000,000	-42,700,000
fiscal year ended june 30, 2020
call premium on debt redemption																	10,000,000
loss on derivative instrument																	24,900,000
decrease/(increase) in trade receivables																	-15,500,000		34,100,000		-29,700,000	-70,600,000	73,700,000		-71,000,000	17,600,000	87,000,000		-15,100,000	-2,500,000	43,900,000		-9,000,000	-30,000,000	59,700,000	-52,100,000	-5,200,000	-12,200,000	62,000,000
decrease/(increase) in inventories																	-54,700,000	-11,600,000	200,000		-17,100,000	-5,000,000	-21,000,000				-7,300,000		-2,300,000	-1,500,000	-16,400,000		-7,300,000	-16,000,000	-20,400,000	10,700,000	-4,700,000	-11,100,000	-14,100,000
net cash (used in)/provided by financing activities																	670,700,000	-101,800,000	-35,800,000		-8,700,000	-55,000,000	-18,800,000									-3,700,000	-6,200,000	-10,600,000	-10,300,000	-12,500,000	-13,600,000	135,700,000	86,900,000
three months ended march 31, 2020
three months ended december 31, 2019
net earnings/																			100,000		-2,900,000	49,000,000	-14,400,000												8,900,000	153,400,000	30,800,000	46,000,000	-19,900,000
non-cash foreign currency transaction (gain)/loss																			-100,000		-4,900,000	1,200,000	2,000,000		7,200,000	-1,200,000	8,300,000		9,100,000	-2,700,000	-700,000		-1,600,000	-3,500,000	-100,000		-2,400,000	-1,200,000	-11,200,000
three months ended september 30, 2019
net revenue																					-5,500,000
cost of sales																					-2,800,000
gross margin																					-2,700,000
earnings from operations before income taxes
income tax expense																					8,600,000
other assets/accrued liabilities, net — current and non-current																					-700,000	-2,200,000	-55,800,000
earnings from continuing operations before income taxes																					-8,700,000
adjustments to reconcile earnings/(loss) from operations to net cash from operations:
1.
adjustments to reconcile earnings from continued operations to net cash from operations:
(increase)/decrease in trade receivables
purchase of redeemable non-controlling interest shares
asset impairments and (gain)/loss on sale of assets																									200,000				1,800,000			1,900,000	-300,000	-100,000	1,200,000	900,000	300,000
amortization and write off of debt financing costs																										1,200,000	1,300,000	1,200,000	1,300,000	3,200,000	1,100,000	1,300,000	1,100,000	1,200,000	1,100,000	1,200,000	1,000,000	1,400,000	12,400,000
cash paid, in lieu of equity, for tax withholding obligations																										-4,000,000	-8,400,000		-2,300,000	-400,000	-100,000		-2,400,000	0	-5,600,000
equity offering, sale of common stock																											277,800,000
net earnings/(loss) from discontinued operations																																				-100,000	0	-200,000	400,000
earnings from continuing operations																															4,600,000	61,900,000	9,800,000
adjustments to reconcile (loss)/earnings from continued operations to net cash from operations:
impairments charges and (gain)/loss on sale of assets
non-cash gain on acquisition																																				1,300,000	0	-3,200,000	-7,000,000
call premium and financing fees paid
net cash provided by/(used in) operating activities from continuing operations																															48,300,000	33,900,000	49,900,000	26,600,000	44,900,000	77,200,000	94,300,000	40,400,000	-40,200,000
net cash provided by/(used in) operating activities from discontinued operations																																				-100,000	0	-200,000	400,000
net cash provided by/(used in) operating activities																														47,700,000	48,300,000	33,900,000	49,900,000	26,600,000	44,900,000	77,100,000	94,300,000	40,200,000	-39,800,000
payment for acquisitions																																				800,000	-6,500,000	-111,600,000	-13,500,000
net cash provided by/(used in) investing activities																														-23,900,000	-114,600,000	-29,900,000	-25,300,000	-49,300,000	-33,200,000	-31,500,000	-43,900,000	-151,700,000	-44,700,000
purchase of redeemable noncontrolling interest shares																																0	0
equity contribution
net cash (used in)/provided by investing activities
net cash provided by/(used in) investing activities from continuing operations																																			-33,200,000	-31,500,000	-43,900,000	-151,700,000	-44,700,000
net cash provided by/(used in) investing activities from discontinued operations
net cash (used in)/provided by financing activities from continuing operations																																			-10,300,000	-12,500,000	-13,600,000	135,700,000	86,900,000
net cash (used in)/provided by financing activities from discontinued operations
reclassification of call premium payments and financing fees paid																																					0	2,800,000	9,800,000
other accrued liabilities and operating items																																	13,800,000	-5,100,000	-44,800,000	12,700,000	29,500,000	-16,100,000	-76,000,000
net change in short-term borrowings																																	800,000				-1,200,000	-5,700,000	11,700,000
equity contribution/																																					0	0	948,800,000
earnings/(loss) from continuing operations																																			8,900,000	153,500,000	30,800,000	46,200,000	-20,300,000
share settlement
balance at june 30, 2014																																						0	891,800,000
additions/
foreign currency translation adjustments																																						-29,200,000	-32,000,000
balance at december 31, 2014
balance at september 30, 2014																																							859,800,000
proceeds from insurance related to long lived assets
payments related to revolver credit facility fees
distribution to noncontrolling interest holder

We provide you with 20 years of cash flow statements for Catalent stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Catalent stock. Explore the full financial landscape of Catalent stock with our expertly curated income statements.

The information provided in this report about Catalent stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.